Analysts Trim Targets Across Defense, Pharma
Wall Street analysts are cutting price targets across defense and pharmaceuticals, even as NVDA keeps attracting bullish upgrades. NVDA's consensus target rose twice in quick succession, now sitting at $273.73. The…